The company said revenue for Q1 2025 was $665 million, up from $650 million a year earlier, with reported growth of 2% and organic growth of 4%. GAAP EPS was $0.35, and adjusted EPS from continuing operations was $1.01.

1. 01

   The company said revenue for Q1 2025 was $665 million, up from $650 million a year earlier, with reported growth of 2% and organic growth of 4%. GAAP EPS was $0.35, and adjusted EPS from continuing operations was $1.01.

2. 02

   Revvity said GAAP operating income from continuing operations for Q1 2025 was $72 million, with an operating margin of 10.9%, up from $44 million (6.8%) a year earlier. Adjusted operating income was $170 million (25.6%), compared with $166 million (25.5%) a year earlier.

3. 03

   The company said Life Sciences revenue for Q1 2025 was $340 million, with organic growth of 2%, and its adjusted operating margin was 31.1%. Diagnostics revenue was $324 million, with organic growth of 5%, and its adjusted operating margin was 22.8%, compared with 24.3% a year earlier.

4. 04

   The company raised its full-year 2025 revenue guidance to $2.83 to $2.87 billion and reaffirmed its organic growth guidance of 3 to 5% and its adjusted EPS guidance of $4.90 to $5.00. Purchases of common stock in Q1 2025 were $153,594 thousand.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.